RU2008112497A - CONJUGATE FOR IMMUNIZATION AND VACCINATION AND METHOD FOR IMPROVING IMMUNOGENITY - Google Patents
CONJUGATE FOR IMMUNIZATION AND VACCINATION AND METHOD FOR IMPROVING IMMUNOGENITY Download PDFInfo
- Publication number
- RU2008112497A RU2008112497A RU2008112497/15A RU2008112497A RU2008112497A RU 2008112497 A RU2008112497 A RU 2008112497A RU 2008112497/15 A RU2008112497/15 A RU 2008112497/15A RU 2008112497 A RU2008112497 A RU 2008112497A RU 2008112497 A RU2008112497 A RU 2008112497A
- Authority
- RU
- Russia
- Prior art keywords
- molecular weight
- conjugate according
- glucose
- immunogen
- peptidoglycan
- Prior art date
Links
Landscapes
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
1. Конъюгат для иммунизации и вакцинации, содержащий иммуноген, ковалентно соединенный с высокомолекулярным носителем, отличающийся тем, что в качестве высокомолекулярного носителя используют кислый пептидогликан с молекулярной массой 1200-40000 кДа, имеющий массовое соотношение между глюкозой и уроновыми кислотами, равное 1:2-4. ! 2. Конъюгат по п.1, отличающийся тем, что пептидная часть молекулы кислого пептидогликана составляет (13±3) мас.%. ! 3. Конъюгат по п.2, отличающийся тем, что сахарный состав полисахаридной части кислого пептидогликана содержит галактуроновую кислоту 18±6%, глюкозу 9±3%, галактозу 5,5±2%, арабинозу 3,8±1,3%, рамнозу 1,9±0,9%, маннозу 0,7±0,25%, а пептидная часть содержит аргинин 2,6%, и лизин 1,8%, а также аспарагиновую кислоту 10,6% и глутаминовую кислоту 11,1%. ! 4. Конъюгат по любому из пп.1-3, отличающийся тем, что иммуноген представляет собой рекомбинантный белок вируса иммунодефицита человека. ! 5. Конъюгат по любому из пп.1-3, отличающийся тем, что иммуноген представляет собой рекомбинантный Е-белок (pE) коронавируса, ассоциированного с атипичной пневмонией. ! 6. Способ повышения иммуногенности антигенов путем ковалентного соединения антигена с кислым пептидогликаном с молекулярной массой 1200-40000 кДа, имеющий массовое соотношение между глюкозой и уроновыми кислотами равное 1:2-4.1. The conjugate for immunization and vaccination, containing an immunogen covalently linked to a high molecular weight carrier, characterized in that the acidic peptidoglycan with a molecular weight of 1200-40000 kDa having a mass ratio between glucose and uronic acids of 1: 2- is used as a high molecular weight carrier four. ! 2. The conjugate according to claim 1, characterized in that the peptide portion of the acidic peptidoglycan molecule is (13 ± 3) wt.%. ! 3. The conjugate according to claim 2, characterized in that the sugar composition of the polysaccharide part of the acidic peptidoglycan contains galacturonic acid 18 ± 6%, glucose 9 ± 3%, galactose 5.5 ± 2%, arabinose 3.8 ± 1.3%, rhamnose 1.9 ± 0.9%, mannose 0.7 ± 0.25%, and the peptide portion contains arginine 2.6%, and lysine 1.8%, as well as aspartic acid 10.6% and glutamic acid 11, one%. ! 4. The conjugate according to any one of claims 1 to 3, characterized in that the immunogen is a recombinant protein of the human immunodeficiency virus. ! 5. The conjugate according to any one of claims 1 to 3, characterized in that the immunogen is a recombinant E-protein (pE) of coronavirus associated with SARS. ! 6. A method of increasing the immunogenicity of antigens by covalently combining an antigen with an acid peptidoglycan with a molecular weight of 1200-40000 kDa, having a mass ratio between glucose and uronic acids of 1: 2-4.
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2008112497/15A RU2378015C2 (en) | 2008-04-02 | 2008-04-02 | Conjugate for immunisation and vaccination and method for improving immunogenicity |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2008112497/15A RU2378015C2 (en) | 2008-04-02 | 2008-04-02 | Conjugate for immunisation and vaccination and method for improving immunogenicity |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2008112497A true RU2008112497A (en) | 2009-10-10 |
RU2378015C2 RU2378015C2 (en) | 2010-01-10 |
Family
ID=41260344
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2008112497/15A RU2378015C2 (en) | 2008-04-02 | 2008-04-02 | Conjugate for immunisation and vaccination and method for improving immunogenicity |
Country Status (1)
Country | Link |
---|---|
RU (1) | RU2378015C2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX363511B (en) * | 2012-08-16 | 2019-03-26 | Pfizer | Glycoconjugation processes and compositions. |
RU2563818C2 (en) | 2013-11-21 | 2015-09-20 | Силезиа Груп Пте. Лтд. | Method of obtaining substance, possessing antimicrobial, antiviral and immunostimulating activity, in particular, with respect to dendrite cells, substance, thereof obtained, and based on it pharmaceutical composition |
RU2743593C1 (en) * | 2020-12-09 | 2021-02-20 | Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) | Peptide immunogens and vaccine composition against covid-19 with the use of peptide immunogens |
RU2743595C1 (en) * | 2020-12-09 | 2021-02-20 | Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) | Vaccine composition against covid-19 |
RU2743594C1 (en) * | 2020-12-09 | 2021-02-20 | Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) | Peptide immunogens used as components of vaccine composition against covid-19 |
RU2752858C1 (en) * | 2021-02-04 | 2021-08-11 | Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) | Integrative plasmid vector pveal2-s-rbd, providing the expression and secretion of the recombinant receptor-binding domain (rbd) of the sars-cov-2 coronavirus in mammalian cells, the recombinant cho-k1-rbd cell line strain and the recombinant sars-cov-2 rbd protein produced by the specified strain of the cell line cho-k1-rbd |
-
2008
- 2008-04-02 RU RU2008112497/15A patent/RU2378015C2/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
RU2378015C2 (en) | 2010-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2008112497A (en) | CONJUGATE FOR IMMUNIZATION AND VACCINATION AND METHOD FOR IMPROVING IMMUNOGENITY | |
EA200800300A1 (en) | Conjugates of immunogenic peptide carriers and methods for their preparation | |
EA200702209A1 (en) | Conjugates of Aβ Immunogenic Peptide Carriers and Methods for Their Production | |
Scaria et al. | Protein-protein conjugate nanoparticles for malaria antigen delivery and enhanced immunogenicity | |
TW200815028A (en) | Conjugation process | |
NZ556533A (en) | Glycoconjugate vaccines containing peptidoglycan | |
BRPI0613525A2 (en) | methods for producing an immunogenic composition, for enhancing the immunogenicity of a composition, for enhancing the immunogenicity of a vaccine composition, and for determining the amount of beta-cross structures in a vaccine composition, uses of beta-cross structures, and an immunogenic composition, subunit vaccine, and immunogenic composition | |
RU2014134288A (en) | IMMUNOGENIC COMPOSITION | |
KR102112663B1 (en) | Salmonella conjugate vaccines | |
RU2017129340A (en) | COMPOSITIONS OF NEISSERIA MENINGITIDIS AND METHODS FOR PRODUCING THEM | |
CN115003330A (en) | Novel glycoconjugates as vaccines and diagnostic tools | |
RU2016110576A (en) | BACTERIAL VACCINE AND METHODS FOR ITS PRODUCTION | |
JP2010523676A5 (en) | ||
CN106659799A (en) | Glycoconjugate vaccines comprising basic units of a molecular construct expressing built-in multiple epitopes for the formulation of a broad-spectrum vaccine against infections due to enteropathogenic bacteria | |
JP2011504535A (en) | Conjugated β-1,3-linked glucan | |
Zhang et al. | Moderate PEGylation of the carrier protein improves the polysaccharide-specific immunogenicity of meningococcal group A polysaccharide conjugate vaccine | |
He et al. | Conjugation of Zika virus EDIII with CRM197, 8-arm PEG and mannan for development of an effective Zika virus vaccine | |
KR20230005313A (en) | Methods for improving the immunogenicity of protein/peptide antigens | |
JP2008537749A (en) | Polymyxin B analog for LPS detoxification | |
KR20060084789A (en) | Vaccines against group y neisseria meningitidis and meningococcal combinations thereof | |
RU2007106900A (en) | IMMUNOGENIC COMPLEXES, METHOD FOR THEIR PREPARATION AND THEIR APPLICATION IN PHARMACEUTICAL COMPOSITIONS | |
BRPI0413906A (en) | HIV immunogenic compositions, kit and related methods | |
He et al. | A SARS-CoV-2 vaccine based on conjugation of SARS-CoV-2 RBD with IC28 peptide and mannan | |
US20090104220A1 (en) | Method to Make a Peptide-Carrier Conjugate with a High Immunogenicity | |
RU2015113230A (en) | Domain CNAB SDRE STAPHYLOCOCCUS AUREUS and its use for vaccination |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20100403 |
|
NF4A | Reinstatement of patent |
Effective date: 20120227 |
|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20150403 |
|
NF4A | Reinstatement of patent |
Effective date: 20160410 |
|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20170403 |